Holen Sie sich die Stockscreener-App
68.90
1.67%
1.13
Handel nachbörslich:
68.90
Schlusskurs vom Vortag:
$67.77
Offen:
$67.77
24-Stunden-Volumen:
770.07K
Relative Volume:
0.64
Marktkapitalisierung:
$5.70B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
8.906
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
+4.97%
1M Leistung:
+9.68%
6M Leistung:
+6.33%
1J Leistung:
+59.34%
1-Tages-Spanne:
$67.77
$70.24
1-Wochen-Bereich:
$66.33
$70.39
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
68.90 | 5.61B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics (PTCT) CMO executes 829-share tax sell-to-cover - stocktitan.net
PTCT (NASDAQ: PTCT) Form 144: Insider proposes sale of 2,265 shares - stocktitan.net
PTC Therapeutics, Inc. (PTCT) stock price, news, quote and history - Yahoo Finance UK
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And DMD Uncertainty - Yahoo Finance
How Investors Are Reacting To PTC Therapeutics (PTCT) Adding Veteran Dealmaker Jessica Chutter To Its Board - Sahm
Almstead, PTC Therapeutics officer, sells $3.59 million in shares By Investing.com - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 52,003 Shares - MarketBeat
PTC Therapeutics (PTCT) officer sells 52,003 shares under 10b5-1 plan - stocktitan.net
PTCT (NASDAQ: PTCT) lists 829 vested shares for resale; insider sales detailed - stocktitan.net
PTC Therapeutics, Inc. (PTCT) Stock forecasts - Yahoo Finance UK
Form 144 | PTC Therapeutics(PTCT.US) Officer Proposes to Sell 3.59 Million in Common Stocks - Moomoo
Insiders sell shares at PTCT (NASDAQ: PTCT) under Rule 144, multiple trades - stocktitan.net
(PTCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jefferies Downgrades PTC Therapeutics (PTCT) to 'Hold' with Pric - GuruFocus
PTC Therapeutics Inc (PTCT) Stock Price Quote Today & Current Price Chart - Capital.com
PTC Therapeutics, Inc. (PTCT) Latest Stock News & Headlines - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Earns "Hold" Rating from Jefferies Financial Group - marketbeat.com
Jefferies Initiates PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $76 - Moomoo
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A. - marketbeat.com
Jefferies downgrades PTC Therapeutics (PTCT) - MSN
Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance? - Sahm
PTC Therapeutics Inc (PTCT) Stock Price, Trades & News - gurufocus.com
Vanguard disaggregates holdings; reports 0 PTC Therapeutics shares (PTCT) - Stock Titan
PTC Therapeutics (PTCT) director receives new stock and option awards - Stock Titan
New PTC Therapeutics (PTCT) director Jessica Chutter files initial Form 3 - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Rating Updates Drive Nasdaq Futures Focus - Kalkine Media
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Truist Financial - MarketBeat
A Look At PTC Therapeutics (PTCT) Valuation As Shares Reflect Mixed Recent Returns - Sahm
PTC Therapeutics adds Jessica Chutter to board of directors By Investing.com - Investing.com India
PTCT SEC FilingsPtc Therapeutics 10-K, 10-Q, 8-K Forms - stocktitan.net
PTC Therapeutics Adds Veteran Banker to Board - TipRanks
PTC Therapeutics Appoints Jessica Chutter To Board - citybiz
Ptc Therapeutics appoints biotech banking pioneer Jessica Chutter to board of directors - marketscreener.com
Ptc Therapeutics, Inc. Appoints Jessica Chutter to Board of Directors, Effective from March 24, 2026 - MarketScreener
PTC Therapeutics appoints Jessica Chutter to its board - TradingView
Biotech banker Jessica Chutter joins PTC Therapeutics (NASDAQ: PTCT) board - Stock Titan
PTC Therapeutics adds Jessica Chutter to board of directors - Investing.com
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors - Yahoo Finance
SG Americas Securities LLC Has $67.94 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Gains Attention After Rating Updates - Kalkine Media
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz - The National Law Review
Assessing PTC Therapeutics (PTCT) Valuation As Rare Disease Growth And Sephience Execution Shape Expectations - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeut - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
PTC Therapeutics or Eli Lilly: Which Stock Has More Upside? - Trefis
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out? - Trefis
Fundamentals Check: How sensitive is PTC Therapeutics Inc to inflationPortfolio Return Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Cinctive Capital Management LP Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Boxer Capital Management LLC Invests $12.27 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):